BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1340@pharmaconomics
DTSTAMP:20260707T015758Z
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260225
SUMMARY:SNY Phase 3 — Dupixent
DESCRIPTION:Phase 3 trial results for Dupixent in allergic fungal rhinosinusitis are due Feb 24\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1121404/000119312526086540/d28705dex991.htm\n\nTrack it: https://pharmaconomics.com/e/1340
URL:https://pharmaconomics.com/e/1340
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SNY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR